The Laboratory For Male Reproductive Research and Testing (CLIA #45D0660126) in the Scott Department of Urology at Baylor College of Medicine now performs UroVysion™ for analysis of urine samples for the presence of bladder cancer cells.* The test is designed to detect aneuploidy for chromosomes 3, 7, 17, and the loss of 9p21 using fluorescent in situ hybridization. Urine samples from patients with hematuria (bladder cancer suspected) are tested with UroVysion™ and analyzed using a Bioview™ Imaging System. The Bioview Duet™ and Solo™ consoles assist in identifying and quantifying these molecular abnormalities via an automated imaging system. UroVysion™ (Abbott Molecular) and Bioview™ are both FDA-approved systems for screening urine specimens for the presence of bladder cancer cells. UroVysion aids in the monitoring for tumor recurrence in patients previously diagnosed with bladder cancer. Results of this test should be used in conjunction with other standard diagnostic procedures. This test can be ordered by physician’s offices, and we will provide specimen collection kits for patient samples that are then delivered to the Laboratory for analysis. Shown below are examples of normal and abnormal cells detected by FISH analysis in urine by UroVysion™ and Bioview™.

Normal cells:

Abnormal cells:

*The UroVysion™ assay does not screen for all forms of bladder cancer. Certain viruses and cancers may yield false positive results. All results, positive or negative, should be confirmed with further diagnostic and clinical testing and correlation.